eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Bausch & Lomb U.K Limited

Bausch & Lomb House, 106 London Road, Kingston-upon-Thames, Surrey, KT2 6TN, UK
Telephone: +44 (0)208 781 2900
Fax: +44 (0)208 781 2901
Medical Information Direct Line: +44(0)1748 828849 or 08 1871 9318
Medical Information e-mail: medicalinformationuk@bausch.com
Customer Care direct line: +44 (0)208781 2991

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 30/07/2008
SPC Minims Fluorescein Sodium 1% w/v


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Minims Fluorescein Sodium 1%


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

1% w/v solution of Fluorescein Sodium Ph.Eur.


Go to top of the page
3. PHARMACEUTICAL FORM

Single-use, sterile eye drops.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

As a diagnostic stain.

Fluorescein does not stain a normal cornea but conjunctival abrasions are stained yellow or orange, corneal abrasions or ulcers are stained a bright green and foreign bodies are surrounded by a green ring.

Fluorescein can be used in diagnostic examinations including Goldmann tonometry and in the fitting of hard contact lenses.


Go to top of the page
4.2 Posology and method of administration

Adults, Children and the Elderly

Instil dropwise into the eye.

Sufficient solution should be applied to stain the damaged areas. Excess may be washed away with sterile saline solution.


Go to top of the page
4.3 Contraindications

Not to be used with soft contact lenses.


Go to top of the page
4.4 Special warnings and precautions for use

Special care should be taken to avoid microbial contamination. Pseudomonas aeruginosa grows well in fluorescein solutions, therefore, a single dose solution is preferred. Each Minims unit should be discarded after a single use.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None known.


Go to top of the page
4.6 Pregnancy and lactation

Safety for use in pregnancy and lactation has not been established, therefore use only when considered essential by the physician.


Go to top of the page
4.7 Effects on ability to drive and use machines

May cause transient blurring of vision on instillation. Warn patients not to drive or operate hazardous machinery until vision is clear.


Go to top of the page
4.8 Undesirable effects

ADRs are very rare(<1/10,000),including isolated reports.

Symptoms of allergic-type reactions and anaphylaxis have been reported following topical ophthalmic administration of Fluorescein sodium and may manifest as:

Eye disorders: allergic conjunctivitis, peri-orbital oedema

Immune system disorders: anaphylactic reaction

Skin and subcutaneous tissue disorders: urticaria, rash


Go to top of the page
4.9 Overdose

Overdose following the recommended use is unlikely.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Fluorescein acts as a diagnostic stain.


Go to top of the page
5.2 Pharmacokinetic properties

Fluorescein will resist penetration of a normal cornea and most excess solution will, therefore, be carried with the tear film away from the conjunctival sac. The majority will be lost through the naso-lacrimal ducts and absorbed via the gastro-intestinal tract from where it is converted rapidly to its glucuronide and excreted via the urine.

If fluorescein crosses the cornea it will enter the Bowman's membrane, stroma and possibly the anterior chamber. Aqueous flow and diffusion into the blood in the anterior chamber finally removes fluorescein from the eye and it is excreted unchanged in the urine.


Go to top of the page
5.3 Preclinical safety data

There are no preclinical data of relevance to the prescriber which are additional to that already included in other sections of this SPC.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Purified Water


Go to top of the page
6.2 Incompatibilities

None known.


Go to top of the page
6.3 Shelf life

Unopened: 15 months.


Go to top of the page
6.4 Special precautions for storage

Store below 25°C. Do not freeze. Protect from light.


Go to top of the page
6.5 Nature and contents of container

A sealed conical shaped polypropylene container fitted with a twist and pull off cap. Each Minims unit contains approximately 0.5ml of solution. Each unit is overwrapped in a polypropylene/paper pouch. 20 units are packed into a suitable carton.


Go to top of the page
6.6 Special precautions for disposal and other handling

Each Minims unit should be discarded after use.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Chauvin Pharmaceuticals Ltd

106 London Road

Kingston-upon-Thames

Surrey

KT2 6TN


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 0033/0079


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first Authorisation: 7 January 1980


Go to top of the page
10. DATE OF REVISION OF THE TEXT

June 2007



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/20208/SPC/


Active Ingredients/Generics

 
   fluorescein sodium